MET and non-small cell lung carcinoma: Primary MET amplification is seen in various solid tumors, most commonly in NSCLC (<1%–5%), gastric cancer (<1%–10%), type I PRCC (papillary renal cell carcinoma) (13%), type II PRCC (3%), colorectal cancer (2%–4%), and with a lower incidence in esophageal and hepatocellular carcinoma.[7] In addition to lung cancer, savolitinib is used to treat PRCC and gastric cancer.